ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Pierre Fabre gets EC nod for Braftovi plus cetuximab to treat BRAFV600E-mutant mCRC
June 08, 2020Pierre Fabre has secured approval from the European Commission (EC) for Braftovi (encorafenib) plus cetuximab (Erbitux) to treat adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy. -
EU nod for new metastatic colorectal cancer combination
June 05, 2020Pierre Fabre's Braftovi (encorafenib) has been approved in Europe for use alongside Erbitux (cetuximab) to treat of adults with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.
Pharma Sources Insight January 2025
